SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-164639
Filing Date
2020-06-09
Accepted
2020-06-09 16:06:20
Documents
13
Period of Report
2020-06-05
Items
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d934672d8k.htm   iXBRL 8-K 50911
2 EX-3.1 d934672dex31.htm EX-3.1 4647
  Complete submission text file 0001193125-20-164639.txt   178022

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA akba-20200605.xsd EX-101.SCH 3051
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE akba-20200605_lab.xml EX-101.LAB 17373
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE akba-20200605_pre.xml EX-101.PRE 10940
13 EXTRACTED XBRL INSTANCE DOCUMENT d934672d8k_htm.xml XML 3236
Mailing Address 245 FIRST STREET CAMBRIDGE MA 02142
Business Address 245 FIRST STREET CAMBRIDGE MA 02142 617-871-2098
Akebia Therapeutics, Inc. (Filer) CIK: 0001517022 (see all company filings)

IRS No.: 208756903 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36352 | Film No.: 20951878
SIC: 2834 Pharmaceutical Preparations